The purity of all final compounds was determined by HPLC analysis and showed purity >95%. Compound
1 (CF53) was purchased form MedChemExpress;
anhydrous dimethylformamide (DMF) was purchased from Acros Organics. The analytical separation was conducted on an Agilent 1100 series HPLC fitted with a diode-array detector, quaternary pump, vacuum degasser, and autosampler. Mass spectrometry data were recorded on an Agilent 6310 ion trap mass spectrometer (ESI source) connected to an Agilent 1200 series HPLC with a quaternary pump, vacuum degasser, diode-array detector, and autosampler.
[
11C]CO
2 was produced via the
14N (p, α)
11C reaction on nitrogen with 2.5% oxygen, with 11 MeV protons (Siemens
Eclipse cyclotron), and trapped on molecular sieves in a TRACERlab FX-MeI synthesizer (General Electric). [
11C]CH
4 was obtained by the reduction of [
11C]CO
2 in the presence of Ni/hydrogen at 350°C and recirculated through an oven containing I
2 to produce
11CH
3I via a radical reaction.
All animal studies were carried out at Massachusetts General Hospital (PHS Assurance of Compliance No. A3596-01). The Subcommittee on Research Animal Care (SRAC) serves as the Institutional Animal Care and Use Committee (IACUC) for the Massachusetts General Hospital (MGH). SRAC reviewed and approved all procedures detailed in this paper.
Bai P., Lan Y., Wang H., Chen Z., Fiedler S., Striar R., Lu X, & Wang C. (2020). Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins. Frontiers in Molecular Biosciences, 7, 198.